Xanomeline (oxalate) [141064-23-5]
Cat# HY-13410-1ml
Size : 10mM/1mL
Brand : MedChemExpress
Xanomeline oxalate (LY246708 oxalate) is a potent and selective muscarinic receptor agonist (SMRA) and stimulates phosphoinositide hydrolysis in vivo. Xanomeline oxalate can be used for the research of Alzheimer’s disease.
For research use only. We do not sell to patients.
Xanomeline oxalate Chemical Structure
CAS No. : 141064-23-5
Based on 1 publication(s) in Google Scholar
Other Forms of Xanomeline oxalate:
- Xanomeline In-stock
- Xanomeline tartrate In-stock
View All mAChR Isoform Specific Products:
Description |
Xanomeline oxalate (LY246708 oxalate) is a potent and selective muscarinic receptor agonist (SMRA) and stimulates phosphoinositide hydrolysis in vivo. Xanomeline oxalate can be used for the research of Alzheimer’s disease[1]. |
IC50 & Target |
muscarinic receptor[1] |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
In Vitro |
Xanomeline stimulates phosphoinositide (PI) hydrolysis in the A9 L m1 cells[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
In Vivo |
Xanomeline robustly stimulates in vivo PI hydrolysis and the effect is blocked by muscarinic antagonists, demonstrating mediation by muscarinic receptors. In mice the ED100 for Xanomeline-induced stimulation of [3H]-IP accumulation is 54 μmole/kg in hippocampus. And in rats the ED100 for Xanomeline-induced stimulation of [3H]-IP accumulation is 8.1 μmole/kg in hippocampus[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||||||
Clinical Trial |
|
||||||||||||||||
Molecular Weight |
371.45 |
||||||||||||||||
Formula |
C16H25N3O5S |
||||||||||||||||
CAS No. |
141064-23-5 |
||||||||||||||||
Appearance |
Solid |
||||||||||||||||
Color |
White to off-white |
||||||||||||||||
SMILES |
CN1CCC=C(C2=NSN=C2OCCCCCC)C1.O=C(O)C(O)=O |
||||||||||||||||
Shipping | Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
Storage |
4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
||||||||||||||||
Solvent & Solubility |
In Vitro:
DMSO : 50 mg/mL (134.61 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage mg/kgAnimal weight Dosing volume Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO
+
%
+
%
Tween-80
+
%
Saline
The co-solvents required include: DMSO,
. All of co-solvents are available by MedChemExpress (MCE).
, Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration:
mg/mL
Method for preparing stock solution:
mg
drug dissolved in
μL
DMSO (Stock solution concentration: mg/mL).
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take
μL DMSO stock solution, add
μL .
μL , mix evenly, next add
μL Tween 80, mix evenly, then add
μL Saline.
If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
|
||||||||||||||||
Purity & Documentation | |||||||||||||||||
References |
|
Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
---|
DMSO | 1 mM | 2.6922 mL | 13.4608 mL | 26.9215 mL | 67.3038 mL |
5 mM | 0.5384 mL | 2.6922 mL | 5.3843 mL | 13.4608 mL | |
10 mM | 0.2692 mL | 1.3461 mL | 2.6922 mL | 6.7304 mL | |
15 mM | 0.1795 mL | 0.8974 mL | 1.7948 mL | 4.4869 mL | |
20 mM | 0.1346 mL | 0.6730 mL | 1.3461 mL | 3.3652 mL | |
25 mM | 0.1077 mL | 0.5384 mL | 1.0769 mL | 2.6922 mL | |
30 mM | 0.0897 mL | 0.4487 mL | 0.8974 mL | 2.2435 mL | |
40 mM | 0.0673 mL | 0.3365 mL | 0.6730 mL | 1.6826 mL | |
50 mM | 0.0538 mL | 0.2692 mL | 0.5384 mL | 1.3461 mL | |
60 mM | 0.0449 mL | 0.2243 mL | 0.4487 mL | 1.1217 mL | |
80 mM | 0.0337 mL | 0.1683 mL | 0.3365 mL | 0.8413 mL | |
100 mM | 0.0269 mL | 0.1346 mL | 0.2692 mL | 0.6730 mL |
Xanomeline oxalate Related Classifications
- GPCR/G Protein Neuronal Signaling
- mAChR